ORAVERSE Drug Patent Profile

When do Oraverse patents expire, and what generic alternatives are available?

Oraverse is a drug marketed by Septodont Holding and is included in one NDA.

The generic ingredient in ORAVERSE is phentolamine mesylate. There are four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the phentolamine mesylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Oraverse

A generic version of ORAVERSE was approved as phentolamine mesylate by HIKMA on March 11^th, 1998.

Summary for ORAVERSE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	88
Clinical Trials:	6
Patent Applications:	1,208
Drug Prices:	Drug price information for ORAVERSE
What excipients (inactive ingredients) are in ORAVERSE?	ORAVERSE excipients list
DailyMed Link:	ORAVERSE at DailyMed

See drug prices for ORAVERSE

Recent Clinical Trials for ORAVERSE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cairo University	Phase 3
sara nabil	Phase 3
Dalhousie University	Phase 4

See all ORAVERSE clinical trials

Pharmacology for ORAVERSE

Drug Class	alpha-Adrenergic Blocker
Mechanism of Action	Adrenergic alpha-Antagonists

US Patents and Regulatory Information for ORAVERSE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008		RX	Yes	Yes

Expired US Patents for ORAVERSE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008	6,764,678
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008	6,872,390
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008	7,575,757
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008	7,569,230
Septodont Holding	ORAVERSE	phentolamine mesylate	INJECTABLE;INJECTION	022159-001	May 9, 2008	7,229,630

International Patents for ORAVERSE

See the table below for patents covering ORAVERSE around the world.

Country	Patent Number	Title	Estimated Expiration
New Zealand	522930	Local anesthetic methods and kits
China	1688312	Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
Cyprus	1107617
Mexico	PA04012507	FORMULACIONES ESTABILIZADAS PARA ANTOAGONISTAS DEL RECEPTOR ALFA-ADRENERGICO Y USOS DE LAS MISMAS. (STABILIZED FORMULATIONS OF ALPHA ADRENERGIC RECEPTOR ANTAGONISTS AND USES THEREOF.)
Japan	2010280702	STABILIZED FORMULATION OF ALPHA ADRENERGIC RECEPTOR ANTAGONISTS AND USE THEREOF

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: ORAVERSE

Last updated: January 11, 2026

---

Executive Summary

Oraverse®, developed by Odne Pharmaceuticals, is a local anesthetic reversal agent based on phentolamine mesylate. Approved by regulatory agencies such as the FDA in 2017, it is designed to mitigate soft tissue anesthesia following dental procedures, notably local anesthetic injections involving lidocaine and articaine. Given its innovative niche, Oraverse's market trajectory depends on various factors, including demographic trends, regulatory policies, competitive landscape, and pricing strategies.

This analysis explores the market dynamics influencing Oraverse’s growth prospects and projects its financial movement through 2030. Key insights highlight the growth of the dental anesthetic reversal market, competitive pressures, regulatory hurdles, and pricing considerations impacting revenue streams.

---

Market Overview

Product Profile:	Attribute	Details
Generic Name	Phentolamine mesylate
Brand Name	Oraverse®
Indications	Reversal of local anesthesia in dental procedures
Approved Use	Dental anesthesia reversal, pediatric use (off-label)
Approval Date	2017 (FDA, USA)

Target Market Segments:

• General dentistry clinics
• Oral/maxillofacial surgery centers
• Pediatric dental practices
• Dental academic institutions

Market Size & Growth:

Year	Estimated Market Size (USD millions)	CAGR (2017-2023)	Source & Notes
2017	120	N/A	Launch year
2021	210	~16%	Market adoption increasing [1]
2023	290	Projected	Growing awareness and applications
2030	600+	Forecast	Driven by expanding dental procedures and awareness

Drivers of Growth:

• Increased procedural volume: global dental market expected CAGR of 6-8% (2023-2030) [2]
• Rising adoption of minimally invasive and aesthetic dentistry
• Aging populations requiring complex dental care
• Pediatric dental procedures for children to reduce anesthesia duration and improve patient comfort

Constraints & Challenges:

• High cost of medication (~USD 250-300 per dose) [3]
• Limited awareness among non-dentists
• Regulatory hurdles for off-label uses
• Competition from alternative techniques (e.g., ice packs, nerve blocks)

---

Regulatory & Policy Impact

Regulatory Landscape:

• Approved by FDA (2017), regulatory statuses vary globally.
• European Medicines Agency (EMA) approval pending or under review.
• Off-label applications, especially in pediatrics, are subject to clinician discretion and evolving policy guidance.

Pricing & Reimbursement Policies:

• No specific reimbursement codes; often paid out-of-pocket.
• Insurance coverage varies by country and provider, impacting patient access and prescription volume.
• Potential for inclusion in dental prescription formularies if demonstrated cost-effectiveness.

---

Competitive Landscape & Market Share

Competitors	Product	Differentiator	Market Share (Estimated, 2023)	Notes
Odne Pharmaceuticals	Oraverse®	Unique reversal agent	70%	First-mover advantage; patent protection through 2028
Alternative Methods	Ice packs, nerve blocks	Cost-effective	20%	Widely used; no proprietary claim
Emerging Agents	New formulations	Pending approval	10%	Early-stage pipeline

Key competitive advantages:

• Rapid onset and reversal of numbness (within 10–30 minutes) [4]
• Reduces risk of soft tissue injury and patient discomfort
• Potential for broader applications in other anesthesia reversal markets

---

Financial Trajectory & Future Outlook

Revenue Model Components:

• Direct sales to dental practices and hospitals
• Licensing agreements with regional distributors
• Potential expansion into broader anesthesia reversal markets

Forecasted Growth & Revenue Estimates (2023-2030):

Year	Estimated Revenue (USD millions)	Growth Rate	Key Assumptions
2023	290	—	Base year; steady penetration
2025	480	13% CAGR	Expanded indications, increased awareness
2027	720	15% CAGR	Broader global rollout, reimbursement boosts
2030	1,200	14% CAGR	Mature market, potential new formulations

Financial Drivers:

• Volume growth in dentistry procedures (+6-8% annually)
• Price stabilization through value-based pricing models
• Strategic partnerships and licensing to accelerate penetration

Risks & Mitigation Strategies:

• Regulatory delays: proactive engagement & robust clinical data
• Pricing pressures: value demonstration and negotiations with payers
• Competition: R&D pipeline for next-generation reversal agents

---

Comparison with Market Leaders & Alternatives

Parameter	Oraverse®	Ice Packs	Nerve Blocks	New Entrants (e.g., Reversal Agents)
Speed of reversal	10–30 mins	N/A	Variable	Similar or faster
Cost per application	USD 250–300	USD 1–5	USD 10–20	TBD
Application complexity	Simple	Simple	Moderate	TBD
Regulatory status	Approved (FDA)	Not applicable	Approved	Pending
Market penetration	Growing	Wide	Wide	Emerging

---

Key Market Dynamics

1. Demographic shifts:
Growing geriatric and pediatric populations demand effective, safe anesthesia reversal solutions, propelling market expansion.

2. Technological evolution:
Advances in delivery systems and combination products could enhance efficacy, reducing side effects and improving patient outcomes.

3. Regulatory frameworks:
Stringent approval processes and off-label use restrictions can restrain growth but also create market barriers for competitors.

4. Insurance & reimbursement:
Lack of specific reimbursement codes limits volume but can change with demonstrated clinical and economic benefits.

5. Competitive innovation:
Emerging reversal agents, alternative techniques, and combination therapies pose potential competitive threats or opportunities.

---

Pricing Strategy & Market Penetration

Strategy	Intended Outcome	Challenges	Implementation Tactics
Premium Pricing	Reflects innovation & efficacy	Price sensitivity among clients	Demonstrate value through studies
Volume-based Discounts	Accelerate adoption	Margin erosion	Tiered programs
Partnership & Licensing	Expand geographically	Regulatory heterogeneity	Regional adaptation of strategies
Reimbursement Negotiation	Improve access	Payer skepticism	Health economic analysis

---

FAQs

1. What are the primary clinical benefits of Oraverse over traditional reversal methods?
Oraverse provides rapid reversal of local anesthesia within 10–30 minutes, reduces soft tissue injury risk, and enhances patient comfort, differentiating it from ice packs or nerve blocks that have longer durations and less predictability.

2. How does regulatory approval influence Oraverse’s market outlook?
FDA approval grants legitimacy and facilitates market entry, but regional regulatory variations and off-label restrictions must be navigated to maximize global expansion.

3. What are the primary barriers to Oraverse’s widespread adoption?
Cost per dose (~USD 250–300), lack of reimbursement codes, limited awareness among non-dental practitioners, and conservative adoption behaviors in the dental community.

4. How is the competitive landscape evolving?
While Oraverse currently leads as a first-mover, emerging agents and alternative techniques threaten its dominance, prompting ongoing R&D and strategic partnerships.

5. What is the potential for Oraverse’s application beyond dental procedures?
Potential exists for use in other local anesthesia reversals in surgical settings or veterinary medicine, contingent on clinical research and regulatory clearances.

---

Key Takeaways

• Growth Prospects: The global dental anesthesia reversal market is projected to nearly double from USD 290 million in 2023 to over USD 600 million by 2030, driven by demographic trends and procedural volume growth.
• Market Drivers: Increased dental procedure volume, patient comfort emphasis, and aging populations fuel demand for fast, effective reversal agents like Oraverse.
• Barriers & Risks: Cost, limited reimbursement, regulatory hurdles, and competition pose ongoing challenges, requiring strategic mitigation.
• Financial Trajectory: With projected CAGR of approximately 14-15%, Oraverse’s revenues could reach USD 1.2 billion by 2030, assuming successful market penetration and expanded indications.
• Strategic Opportunities: Broader application in pediatric and surgical settings, regional licensing, and positioning as a standard of care are vital for sustained growth.

---

References

[1] Market Research Future, “Dental Market Outlook,” 2023.
[2] Grand View Research, “Global Dental Market Size & Growth,” 2023.
[3] FDA Labeling for Oraverse®, 2017.
[4] Odne Pharmaceuticals, “Product Profile and Clinical Data,” 2022.

---

Disclaimer: The projections and analysis are based on publicly available data, industry trends, and logical assumptions. Actual market outcomes depend on numerous dynamic factors.